I9DN Stock Chart & Stats
€3.98
€0.16(5.32%)
At close: 4:00 PM EST
€3.98
€0.16(5.32%)
Day’s Range― - ―
52-Week Range€2.64 - €4.51
Previous CloseN/A
Volume0.00
Average Volume (3M)288.00
Market Cap
€830.42M
Enterprise Value€852.02M
Total Cash (Recent Filing)€95.23M
Total Debt (Recent Filing)€3.91M
Price to Earnings (P/E)5.7
Beta0.23
Next Earnings
Jul 30, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.83
Shares Outstanding197,537,700
10 Day Avg. Volume396
30 Day Avg. Volume288
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)12.04
Price to Sales (P/S)65.44
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)€78.70M
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyThe combination of imdusiran and pegylated interferon alfa-2a was generally safe and well-tolerated, achieving a functional cure in 50% of patients with no serious adverse events.
Financial ManagementArbutus's focus on the efficient deployment of financial resources is driving expectations for a significant reduction in cash burn.
Management And StrategyThe appointment of Lindsay Androski as the new CEO is seen as a strategic move, enhancing the focus on LNP litigation.
Bears Say
Clinical TrialsArbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.
Financial ImpactArbutus anticipates a one-time restructuring charge of approximately $11M-$13M.
Legal ChallengesArbutus and partner Genevant are expanding their LNP legal activity against Moderna globally, adding complexity to ongoing legal proceedings.
Arbutus Biopharma News
I9DN FAQ
What was Arbutus Biopharma’s price range in the past 12 months?
Arbutus Biopharma lowest stock price was €2.64 and its highest was €4.51 in the past 12 months.
What is Arbutus Biopharma’s market cap?
Arbutus Biopharma’s market cap is €830.42M.
When is Arbutus Biopharma’s upcoming earnings report date?
Arbutus Biopharma’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were Arbutus Biopharma’s earnings last quarter?
Arbutus Biopharma released its earnings results on May 13, 2026. The company reported €0.762 earnings per share for the quarter, beating the consensus estimate of -€0.026 by €0.788.
Is Arbutus Biopharma overvalued?
According to Wall Street analysts Arbutus Biopharma’s price is currently Overvalued.
Does Arbutus Biopharma pay dividends?
Arbutus Biopharma does not currently pay dividends.
What is Arbutus Biopharma’s EPS estimate?
Arbutus Biopharma’s EPS estimate is -0.02.
How many shares outstanding does Arbutus Biopharma have?
Arbutus Biopharma has 197,537,700 shares outstanding.
What happened to Arbutus Biopharma’s price movement after its last earnings report?
Arbutus Biopharma reported an EPS of €0.762 in its last earnings report, beating expectations of -€0.026. Following the earnings report the stock price went up 0.276%.
Which hedge fund is a major shareholder of Arbutus Biopharma?
Currently, no hedge funds are holding shares in DE:I9DN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arbutus Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.34%
12-Months-Change
Fundamentals
Return on Equity
129.32%
Trailing 12-Months
Asset Growth
136.87%
Trailing 12-Months
Company Description
Arbutus Biopharma
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Technical Analysis
Options Prices
Currently, No data available
---